Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
The companies also agreed to a clinical trial collaboration to evaluate ivonescimab with sonesitatug vedotin in gastrointestinal cancers. Summit said AstraZeneca’s investment will be in convertible preferred shares.
Summit Therapeutics Inc (NASDAQ:SMMT) said Phase III BTC topline data showing overall survival superiority will be presented at ESMO 2026 while the company advances licensed ivonescimab, a dual—action bispecific antibody approved in China but still investigational in its U.S. and EU territories.Pre…
SMMT's Ivonescimab is approved in China for first-line treatment of squamous non-small cell lung cancer